Back to search

Article

The real-world therapeutic analysis of first-line immunotherapy in Chinese patients with Drive Gene Positive for Advanced Non-Small Cell lung cancer

2022-05-31

Abstract excerpt

<h4>Background: </h4> Immune checkpoint inhibitors are widely used in advanced non-small cell lung cancer, but in some studies it has been shown that patients with genetic mutations didn't benefit from immunotherapy. Our aim was to explore the efficacy of programmed death-1 (PD-1) and programmed death-receptor-ligand 1 (PD-L1) inhibitors in the first-line treatment of advanced NSCLC with driver gene mutations in r...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
4a627f7a-35dd-57de-84c0-dcc42079387d
DOI
10.21203/rs.3.rs-1692856/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The real-world therapeutic analysis of first-line immunotherapy in Chinese patients with Drive Gene Positive for Advanced Non-Small Cell lung cancerDOI 10.21203/rs.3.rs-1692856/v1
[Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2023 edition)].Semantic proximity
[Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2022 edition)].Semantic proximity
[The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].Semantic proximity
Chinese expert consensus on immunotherapy for advanced non-small cell lung cancer with oncogenic driver mutations (2023 edition).Semantic proximity
[Chinese Expert Consensus on Second-line Treatment for Non-small Cell Lung Cancer with Negative Driver Gene Mutations].Semantic proximity
A Study on the Efficacy of Immune Checkpoint Inhibitors Combined with Chemotherapy in Patients with Oligometastatic Driver Gene-Negative Non-Small Cell Lung Cancer Undergoing RadiotherapySemantic proximity
The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy.Semantic proximity
Immune Checkpoint Inhibitor without Pemetrexed for First-line Maintenance Therapy in Advanced Lung Adenocarcinoma: A real-world retrospective studySemantic proximity
Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis.Semantic proximity
Update in Immunotherapy for Advanced Non-small Cell Lung Cancer: Treatment Sequencing and Best ChoicesSemantic proximity
Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterations.Semantic proximity
PD-1/L1 immune checkpoint inhibitors for KRAS-mutant non-small cell lung cancer: a multicenter retrospective real-world studySemantic proximity
Select a neighboring publication to make it the new centre.